

Effective Date: 17 Nov 2015

SAFETY DATA SHEET

Section 1: Identification			
Section 1, Identification			
Product	Ketorolac Tromethamine Injection USP		
Distributor	SOLA Pharmaceuticals		
	655 Highlandia Drive, Ste B		
	Baton Rouge, LA. 70810		
	Tel: 866.747.7365		
	Fax: 800.754.9550		
	www.solameds.us		
	info@solameds.us		
NDC Number	70512-842-25 (15mg/mL) (1mL vial)		
	70512-843-25 (30mg/mL) (1mL vial)		
	Section 2: Hazard(s) Identification		
Section 2, Hazard(s) Identifi	cation		
Classification of the Substar	nce or Mixture		

GHS – Classification Reproductive Toxicity: Category 1A

Specific target organ systemic toxicity (repeated exposure): Category 2

Label Elements

Signal Word Danger

Hazard Statements H360D – may damage the unborn child

H373 – may cause damage to organs through prolonged or repeated exposure

Precautionary Statements P201 – obtain special instructions before use

P202 – do not handle until all safety precautions have been read and understood

P260 – do not breathe dust/fume/gas/mist/vapors/spray

P280 – wear protective gloves/protective clothing/eye protection/face protection

P308 + P313 – IF exposed or concerned: get medical attention/advise

P314 – get medical attention/advise if you feel unwell

P405 - store locked up

P501 – dispose of contents/container in accordance with all local and national

regulations



Other Hazards Note An Occupational Exposure Value has been established for one or more of the

Ingredients (see Section 8).



Effective Date: 17 Nov 2015

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: Composition/Information on Ingredients

Section 3, Composition/Information on Ingredients

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Ethanol	64-17-5	200-578-6	Flam. Liq. 2 (H225)	7 – 12
Ketorolac tromethamine	74103-07-4	Not listed	Acute Tox. 3 (H301) STOT RE 2 (H373) Repr. 1A (H360D)	1.5 – 3.0
Sodium hydroxide	1310-73-2	215-185-5	Skin Corr. 1A (H314)	Adjust to pH
Hydrochloric acid	7647-01-0	231-595-7	Press. Gas Skin Corr. 1A (314) Acute Tox. 3 (H331)	Adjust to pH
Sodium chloride	7647-14-5	231-598-3	Not listed	0.4 - 0.7
Water for injection	7732-18-5	231-791-2	Not listed	Qs to 100%

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16.

Section 4: First-Aid Measures

Section 4, First-Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention

immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects For information on potential signs and symptoms of exposure, See Section 2 – Hazards

Of Exposure: Identification and/or Section 11 - Toxicological Information.

Medical Conditions None known

Aggravated by Exposure

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician None

Section 5: Fire-Fighting Measures

Section 5, Fire-Fighting Measures

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Special Hazaards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire. Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters During all firefighting activities, wear appropriate protective equipment,



Effective Date: 17 Nov 2015

Including self-contained breathing apparatus.

Section 6: Accidental Release Measures

Section 6, Accidental Release Measures

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective

equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of the spill or leak. Absorb spills with non-combustible

absorbent material and transfer into a labeled container for disposal. Clean

spill area thoroughly. Prevent discharge to

Measures for Environmental

Large Spills:

Place waste in an appropriately labeled, sealed container for disposal. Care

Protections: should be taken to avoid environmental release.

Additional Consideration for Non-essential personnel should be evacuated from affected area. Report

emergency situations immediately. Clean-up operations should only be

undertaken by trained personnel.

Section 7: Handling and Storage

Section 7, Handling and Storage

Precautions for Safe Handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific End Use(s): Pharmaceutical product used as non-steroidal, anti-inflammatory drug (NSAID)

Section 8: Exposure Controls / Personal Protection

Section 8, Exposure Controls / Personal Protection

Control Parameeters

Refer to available public information for specific member-state Occupational Exposure Limits.

Ketorolac Tromethamine

Finland OEL - TWA

Capiin OEL TWA-8Hr:	30 μg/m ⁹

Ethanol

ACGHI Threshold Limit Value (STEL)	1000 ppm
Australia TWA	1000 ppm

Australia OEL – MAKS	1000 ppm
----------------------	----------

1900 mg/m³

Belgium OEL - TWA 1000 ppm 1907 mg/m³


1000.0 mg/m³

Bulgaria OEL - TWA Czech Republic OEL - TWA 1000 mg/m³ Denmark OEL - TWA 1000 ppm 1900 mg/m³

500 ppm


Estonia OEL - TWA

1000 mg/m³ 1000 ppm





1900 mg/m³ France OEL - TWA 1000 ppm 1900 mg/m³ Germany - TRGS 900 - TWAs 500 ppm 960 mg/m³ Germany (DFG) - MAK 500 ppm 960 mg/m³ Greece OEL - TWA 1000 ppm 1900 mg/m³ 1900 mg/m³ Hungary OEL – TWA Latvia OEL - TWA 260 mg/m³ 500 ppm Lithuania OEL - TWA 1000 mg/m³ Netherlands OEL - TWA 260 mg/m³ OSHA - Final PELS - TWAs 1000 ppm 1900 mg/m³ 1900 mg/m³ Poland OEL – TWA 1000 ppm Portugal OEL – TWA Romania OEL - TWA 1000 ppm 1900 mg/m³ 1000 mg/m³ Russia OEL - TWA Slovakia OEL – TWA 500 ppm 960 mg/m³ Slovenia OEL - TWA 1000 ppm 1900 mg/m³ Sweden OEL – TWA 500 ppm 1000 mg/m³ 500 ppm Switzerland OEL – TWAs 960 mg/m³ Vietnam OEL – TWAs 1000 mg/m³ **Sodium Hydroxide ACGIH Ceiling Threshold Limit** 2 mg/m^3 Australia PEAK 2 mg/m^3 2 mg/m^3 Austria OEL – MAKs Bulgaria OEL - TWA 2.0 mg/m^3 1 mg/m³ Czech Republic OEL – TWA Estonia OEL - TWA 1 mg/m³ 2 mg/m^3 France OEL – TWA 2 mg/m^3 Greece OEL – TWA Hungary OEL - TWA 2 mg/m^3 2 mg/m3 Japan – Oels – Ceilings Latvia OEL - TWA 0.5 mg/m³ 2 mg/m^3 OSHA - Final PELS - TWAs Poland OEL - TWA 0.5 mg/m³ Slovakia OEL - TWA 2 mg/m^3 Slovenia OEL – TWA 2 mg/m³ Sweden OEL - TWAs 1 mg/m³





Switzerland OEL – TWAs	2 mg/m ³	
Sodium Chloride		
Latvia OEL – TWA	5 mg/m ³	
Lithuania OEL – TWA	5 mg/m ³	
Hydrochloric Acid		
ACGIH Ceiling Threshold Limit	2 ppm	
Australia PEAK	5 ppm	
	7.5 mg/m ³	
Austria OEL – MAKs	5 ppm	
	8 mg/m ³	
Belgium OEL – TWA	5 ppm	
	8 mg/m ³	
Bulgaria OEL – TWA	5 ppm	
	8 mg/m ³	
Cyprus OEl – TWA	5 ppm	
	8 mg/m ³	
Czech Republic OEL – TWA	8 mg/m ³	
Estonia OEL – TWA	5 ppm	
	8 mg/m ³	
Germany – TRGS 900 - TWAs	2 ppm	
·	3.0 mg/m ³	
Greece OEL – TWA	5 ppm	
	7 mg/m ³	
Hungary OEL – TWA	8 mg/m ³	
Ireland OEL – TWA	5 ppm	
	8 mg/m ³	
Italy OEL – TWA	5 ppm	
	8 mg/m ³	
Japan – Oels – Ceilings	2 ppm	
	3.0 mg/m ³	
Latvia OEL – TWA	5 ppm	
	8 mg/m ³	
Lithuania OEL – TWA	5 ppm	
	8 mg/m ³	
Luxembourg OEL – TWA	5 ppm	
	8 mg/m ³	
Malta OEL – TWA	5 ppm	
	8 mg/m ³	
Netherlands OEL – TWA	8 mg/m ³	
Poland OEL - TWA	5 mg/m ³	
Portugal OEL – TWA	5 ppm	
	8 mg/m ³	
Romania OEL – TWA	5 ppm	
	8 mg/m ³	
Slovakia OEL – TWA	5 ppm	
	8 mg/m ³	



Effective Date: 17 Nov 2015

Slovenia OEL – TWA 5 ppm

8 mg/m³

Spain OEL – TWA 5 ppm

7.6 mg/m³

Switzerland OEL – TWAs 2 ppm

 3.0 mg/m^3

Vietnam OEL – TWAs 5 mg/m³

Sodium Chloride

Caplin Occupational Exposure OEB 1 (control exposure to the range of 1000ug/m³ to 3000ug/m³) Band (OEB):

Exposure Controls

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Hands

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

Eyes

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

Respiratory Protection

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

Section 9: Physical and Chemical Properties

Section 9, Physical and Chemical Properties

Information on Basic Physical and Chemical Properties

Physical State Solution

ColorClear to light yellowOdor ThresholdNo data available

Molecular Weight Mixture



Effective Date: 17 Nov 2015

Odor Alcohol slight
Molecular Formula Mixture

Solvent SolubilityNo data availableWater SolubilityNo data available

pH 6.9 – 7.9

Melting/Freezing Point (C°)

No data available

Boiling Point (C°)

No data available

Partition Coefficient: (Method, pH, Endpoint, Value)
Ketorolac tromethamine
Ethanol
Water for injection
Hydrochloric acid
Sodium hydroxide
No data available
No data available
No data available

Decomposition Temperature (C°)No data availableEvaporation Rate (Gram/s)No data availableVapor Pressure (kPa)No data availableVapor Density (g/mL)No data availableRelative DensityNo data available

Specific Gravity 0.991

Viscosity No data available

Flammability

Autoignition Temperature (Solid) (C°)

Flammability (Solids)

Flash Point Liquid (C°)

Upper Explosive Limits (Liquid) (% by Vol.)

Lower Explosive Limits (Liquid) (% by Vol.)

Polymerization

No data available
No data available
Will not occur

Section 10: Stability and Reactivity

Section 10, Stability and Reactivity

Reactivity No data available

Chemical Stability Stable under normal conditions of use

Possibility of Hazardous Reactions

Oxidizing Properties No data available

Conditions to Avoid Fine particles (such as mists) may fuel fires/explosions. As a precautionary

measure, keep away from heat sources and electrostatic discharge.

Incompatible Materials As a precautionary measure, keep away from strong oxidizers.

Hazardous Decomposition No data available

Products

Section 11: Toxicological Information

Section 11, Toxicological Information

Information on Toxicological Effect

General Information The information included in this section describes the potential hazards of

the individual ingredients.

Short Term Accidential ingestion may cause effects similar to those seen in clinical use.

Individuals sensitive to this chemical or other materials in its chemical class



Effective Date: 17 Nov 2015

may develop allergic reactions.

Known Clinical EffectsOther nonsteroidal anti-inflammatory drugs (NSAIDs) are known to impact delivery,

late fetal development, and lactation. Ingestion of this material may cause effects similar to those seen in clinical use including serious gastrointestinal toxicity such as bleeding, ulceration, and perforation and kidney toxicity. Clinical use of this drug has caused headache, dizziness, blurred vision, ringing of the ears, skin rash, itching,

swelling, and liver effects.

Acute Toxicity: (Species, Route End Point, Dose)

Sodium Chloride

Rat Oral LD50 3000 mg/kg Mouse Oral LD50 4000 mg/kg

Ketorolac tromethamine

Rat Oral LD50 189 mg/kg Mouse Oral LD50 293 mg/kg

Ethanol

Mouse Oral LD50 3,450 g/m³
Rat Oral LD50 7,050 mg/kg

Mouse Inhalation LC50 4h 39 g/m³
Rat Inhalation LC50 10h 20,000 ppm

Sodium hydroxide

Mouse IP LD50 40mg/kg

Irritation/Sensitization: (Study Type, Species, Severity)

Sodium chloride

Eye Irritation Rabbit Moderate
Skin Irritation Rabbit Mild

Ethanol

Eye Irritation Rabbit Severe

Hydrochloric acid

Skin Irritation Severe Eye Irritation Severe

Sodium hydroxide

Eye Irritation Rabbit Severe Skin Irritation Rabbit Severe

Reproduction and Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s)

Ketorolac tromethamine

Reproductive & Fertility – Females	Rat	Oral	16mg/kg/day	NOAEL	Negative
Reproductive & Fertility – Males		Oral	9mg/kg/day	NOAEL	Negative
Prenatal & Postnatal Development	Rabbit	Oral	3.6mg/kg/day	NOAEL	Negative
Prenatal & Postnatal Development	Rat	Oral	10mg/kg/day	NOAEL	Negative



Effective Date: 17 Nov 2015

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Ketorolac tromethamine

Bacterial Mutagenicity (Ames) Salmonella, E.coli Negative Unscheduled DNA Synthesis Not specified Negative In Vivo Micronucleus Mouse Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Ketorolac tromethamine

24 Month(s) Rat Oral 5mg/kg/day NOAEL Not carcinogenic 18 Month(s) Mouse Oral 2mg/kg/day NOAEL Not carcinogenic

Carcinogen Status Carcinogenicity of the mixture has not been determined. Alcohol is listed as

IARC. The IARC monograph examining the carcinogenic potential of ethanol only

alcoholic beverages. See below.

Ethanol IARC Group 1 (Carcinogenic to Humans)

Hydrochloric Acid IARC Group 3 (not Classifiable)

Section 12: Ecological Information

Section 12, Ecological Information

Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Ethanol

Fathead Minnow NPDES LC50 24 hours 11,200 mg/L Oncorhynchus mykiss NPDES LC50 96 hours 12,900 mg/L (Rainbow Trout)

Pimephales promelas NPDES LC50 96 hours 14,200 mg/L

(Fathead Minnow)

Persistence and DegradabilityNo data availableBio-accumulative PotentialNo data availableMobility in SoilNo data available

Section 13: Disposal Considerations

Section 13, Disposal Considerations

Waste Treatment Methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: Transport Information

Section 14, Transport Information

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, UEADR, IATA, or IMDG regulations.



Effective Date: 17 Nov 2015

Section 15: Regulatory Information

Section 15, Regulatory Information

Safety, Health and Environmental

Regulations/Legislation Specific for the Substance or Mixture

Ketorolac tromethamine

CERCLA/SARA 313 Emission Reporting

California Proposition 65

Australia (AICS)

Not listed

Not listed

Not listed

Standard for the Uniform Scheduling

Schedule 4

for Drugs and Poisons

EU EINECS/ELINCS List Not listed

Ethanol

CERCLA/SARA 313 Emission Reporting Not listed

California Proposition 65 carcinogen 4/29/2011 in alcoholic beverages

Developmental toxicity 10/1/1987 in alcoholic beverages

Inventory – United States TSCA – Sect. 8(b)

Australia (AICS)

Present

EU EINECS/ELINCS List

200-578-6

Sodium Chloride

CERCLA/SARA 313 Emission Reporting

California Proposition 65

Inventory – United States TSCA – Sect. 8(b)

Australia (AICS)

EU EINECS/ELINCS List

Not listed

Not listed

Present

231-598-3

Sodium Hydroxide

CERCLA/SARA 313 Emission Reporting Not listed CERCLA/SARA Hazardous Substances and 1000 lb Their Reportable Quantities 454 kg California Proposition 65 Not listed Inventory – United States TSCA – Sect. 8(b) Present Australia (AICS) Present Standard for the Uniform Scheduling Schedule 5 For Drugs and Poisons Schedule 6 **EU EINECS/ELINCS List** 215-185-5

Water for Injection

CERCLA/SARA 313 Emission Reporting
California Proposition 65
Inventory – United States TSCA – Sect. 8(b)
Australia (AICS)
REACH – Annex IV – Exemptions from the
Present

Obligations of Register

EU EINECS/ELINCS List 200-578-6



Effective Date: 17 Nov 2015

Hydrochloric Acid

CERCLA/SARA 313 Emission Reporting 1.0%
CERCLA/SARA Hazardous Substances and their 5000 lb
Reportable Quantities 2270 kg
CERCLA/SARA – Section 302 Extremely 500 lb

Hazardous TPQs

California Proposition 65
Inventory – United States TSCA – Sect. 8(b)
Australia (AICS)
Present
Standard for the Uniform Scheduling
For Drugs and Poisons
Schedule 6
EU EINECS/ELINCS List
Not listed
Not listed
Present
Schedule 5
Schedule 6
EU EINECS/ELINCS List
231-595-7

Section 16: Other Information

Section 16, Other Information

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.3; H301 - Toxic if swallowed Acute toxicity, inhalation-Cat.3; H331 - Toxic if inhaled Skin corrosion/irritation-Cat.1A; H314 - Causes severe skin burns and eye damage Reproductive toxicity-Cat.1A; H360D - May damage the unborn child Specific target organ toxicity, repeated exposure-Cat.2; H373 - May cause damage to organs through prolonged or repeated exposure Flammable liquids-Cat.2; H225 - Highly flammable liquid and vapor.

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

SOLA shall not be held liable for any damage resulting from handling or from contact with the above product. SOLA reserves the right to revise this Safety Data Sheet.